SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

被引：0

作者：

Qin, Shuqui ^{[1
]}

Li, Jin ^{[2
]}

Zhou, Aiping ^{[3
]}

Zhang, Yanqiao ^{[4
]}

Yuan, Xianglin ^{[5
]}

Zhu, Liangjun ^{[6
]}

Qin, Baoli ^{[7
]}

Zeng, Shan ^{[8
]}

Shen, Lin ^{[9
]}

Yuan, Ying ^{[10
]}

Wang, Weibo ^{[11
]}

Liang, Jun ^{[12
]}

Zhang, Xianwen ^{[13
]}

Ye, Feng ^{[14
]}

Chen, Ping ^{[15
]}

Wang, Huaizhang ^{[16
]}

Yu, Zhenyan ^{[17
]}

Yue, Lu ^{[18
]}

Fang, Yong ^{[19
]}

Xiong, Jianping ^{[20
]}

Yang, Jianwei ^{[21
]}

Wan, Yiye ^{[22
]}

Yin, Xianli ^{[23
]}

Wang, Wenling ^{[24
]}

Xu, Nong ^{[25
]}

Wang, Xiaohong ^{[26
]}

Xiao, Zemin ^{[27
]}

Su, Huafang ^{[28
]}

Wang, Ying ^{[29
]}

Gu, Kangsheng ^{[30
]}

Tu, Shuiping ^{[31
]}

Wang, Zishu ^{[32
]}

Liu, Bo ^{[33
]}

Hu, Xiaohua ^{[34
]}

Liu, Weixian ^{[35
]}

Li, Xiaofeng ^{[36
]}

机构：

[1] Nanjing Jiangning Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China

[2] Shanghai East Hosp, Dept Med Oncol, 1,800 Yuntai Rd, Shanghai 200123, Peoples R China

[3] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing, Peoples R China

[4] Harbin Med Univ, Canc Hosp, Dept Pathol, Harbin, Heilongjiang, Peoples R China

[5] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Med Oncol, R China, Wuhan, Hubei, Peoples R China

[6] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[7] Liaoning Canc Hosp & Inst, Dept Gastroenterol, Shenyang, Liaoning, Peoples R China

[8] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China

[9] Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China

[10] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[11] Shandong Prov Hosp, Dept Chemotherapy, Jinan, Peoples R China

[12] Peking Univ, Int Hosp, Dept Med Oncol, Beijing, Peoples R China

[13] Northern Jiangsu Peoples Hosp, Dept Med Oncol, Yangzhou, Jiangsu, Peoples R China

[14] Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen, Fujian, Peoples R China

[15] Ningxia Med Univ, Gen Hosp, Dept Med Oncol, Yinchuan, Ningxia, Peoples R China

[16] Henan Canc Hosp, Dept Integrated Chinese & Western Med, Zhengzhou, Henan, Peoples R China

[17] Mudanjiang Tumor Hosp, Dept Med Oncol, Mudanjiang, Heilongjiang, Peoples R China

[18] Qingdao Municipal Hosp Grp, Dept Oncol, Qingdao, Shandong, Peoples R China

[19] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[20] Nanchang Univ, Affiliated Hosp 1, Dept Med Oncol, Nanchang, Jiangxi, Peoples R China

[21] Fujian Canc Hosp, Dept Abdominal Oncol, Fuzhou, Fujian, Peoples R China

[22] Jiangxi Canc Hosp, Dept Gastroenterol, Nanchang, Jiangxi, Peoples R China

[23] Cent South Univ, Canc Hosp, Xiangya Sch Med, Dept Gastroenterol & Urol, Changsha, Hunan, Peoples R China

[24] Guizhou Med Univ, Dept Abdominal Oncol, Affiliated Hosp, Guiyang, Guizhou, Peoples R China

[25] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[26] Zhejiang Canc Hosp, Dept Abdominal Oncol, Hangzhou, Zhejiang, Peoples R China

[27] First Peoples Hosp Changde City, Dept Oncol, Changde, Hunan, Peoples R China

[28] Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Wenzhou, Zhejiang, Peoples R China

[29] China Med Univ, Shengjing Hosp, Dept Med Oncol, Shenyang, Liaoning, Peoples R China

[30] Anhui Med Univ, Affiliated Hosp 1, Dept Med Oncol, Hefei, Anhui, Peoples R China

[31] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Med Oncol, Shanghai, Peoples R China

[32] First Affiliated Hosp, Bengbu Med Coll, Dept Med Oncol, Bengbu, Anhui, Peoples R China

[33] Shandong Canc Hosp & Inst, Dept Gastroenterol, Jinan, Shandong, Peoples R China

[34] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning, Guangxi, Peoples R China

[35] Binzhou Peoples Hosp, Dept Med Oncol, Binzhou, Shandong, Peoples R China

[36] Quanzhou First Hosp, Dept Med Oncol, Quanzhou, Fujian, Peoples R China

来源：

CANCER COMMUNICATIONS | 2024年 / 44卷 / 08期

关键词：

D O I：

10.1002/cac2.12586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：910 / 914

页数：5

共 50 条

[21] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
Toshi Takaoka
Tetsuo Kimura
Rai Shimoyama
Shunji Kawamoto
Kazuki Sakamoto
Fuminori Goda
Hiroshi Miyamoto
Yuji Negoro
Akihito Tsuji
Koji Yoshizaki
Takahiro Goji
Shinji Kitamura
Hiromi Yano
Koichi Okamoto
Masako Kimura
Toshiya Okahisa
Naoki Muguruma
Yoshiro Niitsu
Tetsuji Takayama
Cancer Chemotherapy and Pharmacology, 2016, 78 : 397 - 403
[22] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
Takaoka, Toshi
Kimura, Tetsuo
Shimoyama, Rai
Kawamoto, Shunji
Sakamoto, Kazuki
Goda, Fuminori
Miyamoto, Hiroshi
Negoro, Yuji
Tsuji, Akihito
Yoshizaki, Koji
Goji, Takahiro
Kitamura, Shinji
Yano, Hiromi
Okamoto, Koichi
Kimura, Masako
Okahisa, Toshiya
Muguruma, Naoki
Niitsu, Yoshiro
Takayama, Tetsuji
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 397 - 403
[23] FOLFIRI versus irinotecan monodrug as second-line treatment in metastatic colorectal cancer patients: An open, multicenter, prospective, randomized controlled phase III clinical study.
Guo, Weijian
Zhang, Xiaowei
Wang, Yusheng
Zhang, Wen
Liu, Xin
Shen, Wei
He, Yifu
Zhu, Xiaodong
Chen, Zhiyu
Wang, Hong Qiang
Huang, Mingzhu
Zhang, Zhe
Zhao, Xiaoying
Qiu, Lixin
Wang, Chenchen
Sheng, Xuedan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer -: Mature results of a multicenter phase II study
Aparicio, J
Vicent, JM
Maestu, I
Bosch, C
Galán, A
Busquier, I
Llorca, C
Garcerá, S
Campos, JM
López-Tendero, P
Balcells, M
ONCOLOGY, 2005, 68 (01) : 58 - 63
[25] Cost-effectiveness of Capecitabine plus Irinotecan Versus Leucovorin plus Fluorouracil plus Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China
Wu, Qiuji
Zhang, Pengfei
Wang, Xinyuan
Zhang, Mengxi
Liao, Weiting
Li, Qiu
CLINICAL THERAPEUTICS, 2020, 42 (11) : 2148 - +
[26] A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon
Temraz, Sally
Nasr, Fadi
Kattan, Joseph
Abigerges, Dany
Moukadem, Walid
Farhat, Fadi
Maatouk, Layal
Chahine, Georges
Shamseddine, Ali
BIOLOGICS-TARGETS & THERAPY, 2022, 16 : 7 - 15
[27] Second-line treatment with oxaliplatin plus raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy
Scheithauer, W
Kornek, GV
Schuell, B
Ulrich-Pur, H
Penz, M
Raderer, M
Lang, F
Schneeweiss, B
Lenauer, A
Depisch, D
ANNALS OF ONCOLOGY, 2001, 12 (05) : 709 - 714
[28] Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy forMetastatic Colorectal Cancer
Louvet, C.
Andre, T.
Gamelin, E.
Hebbar, M.
Mabro, M.
Bennamoun, M.
Rassam, H.
de Gramont, A.
JOURNAL OF ONCOLOGY, 2010, 2010
[29] A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
Suenaga, Mitsukuni
Mizunuma, Nobuyuki
Matsusaka, Satoshi
Shinozaki, Eiji
Ozaka, Masato
Ogura, Mariko
Chin, Keisho
Yamaguchi, Toshiharu
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1653 - 1662
[30] Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan plus Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
Sobrero, Alberto
Lenz, Heinz-Josef
Eng, Cathy
Scheithauer, Werner
Middleton, Gary
Chen, Wenfeng
Esser, Regina
Nippgen, Johannes
Burris, Howard
ONCOLOGIST, 2021, 26 (02): : E261 - E269

← 1 2 3 4 5 →